Brief: Bioage Labs Announces Discontinuation Of Strides Phase 2 Clinical Trial
06/12/2024 21:40
Dec 6 (Reuters) - BIOAGE Labs Inc BIOA.O :
* BIOAGE LABS ANNOUNCES DISCONTINUATION OF STRIDES PHASE 2
CLINICAL TRIAL EVALUATING AZELAPRAG IN COMBINATION WITH
TIRZEPATIDE FOR THE TREATMENT OF OBESITY
* BIOAGE LABS INC - NO TRANSAMINASE ELEVATIONS IN
TIRZEPATIDE ONLY
GROUP
* BIOAGE LABS INC - DECISION FOLLOWS OBSERVATIONS OF LIVER
TRANSAMINITIS WITHOUT CLINICALLY SIGNIFICANT SYMPTOMS IN SOME
SUBJECTS ON AZELAPRAG
* BIOAGE LABS INC - DOSING DISCONTINUED, NO ADDITIONAL
SUBJECTS TO
BE ENROLLED
Source text: ID:nGNX5JjjwD
Further company coverage: BIOA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioAge Labs
See all newsBrief: Bioage Labs Announces First Participant Dosed In Quell-Dme, A Phase 2 Trial Of Bge-102, A Novel Oral Nlrp3 Inhibitor, In Diabetic Macular Edema
BioAge Labs, Inc. reports results for the quarter ended June 30 - Earnings Summary
BioAge Labs Q1 collaboration revenue beats estimates on Novartis collaboration
BioAge Labs full-year collaboration revenue beats estimates
U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP